Keywords
cytoreductive surgery - mucinous adenocarcinoma - neoadjuvant chemotherapy - ovarian
cancer
Introduction
Primary mucinous epithelial ovarian adenocarcinoma (mEOC) constitutes a small percentage
(2–5%) of ovarian cancers, with distinct clinicopathological characteristics when
compared with the more common serous histology.[1]
[2] The representation of mEOC in large clinical trials exploring the role of therapeutic
interventions is small; for example, 1.6% in the Gynecologic Oncology Group (GOG)
182 trial.[3] This subset of tumors has a low response to primary chemotherapy. There is no gold
standard method to distinguish unequivocally between mEOC and mucinous carcinomas
metastatic to the ovary.
Materials and Methods
This is a retrospective study of a series of primary mEOC diagnosed and treated at
a premier tertiary care center in India, from January 1, 2005, to December 31, 2012.
The archived case records were studied in detail, including the clinical history and
examination, imaging, endoscopy, biopsy, and histopathological reports. The following
parameters were collected: age, date of admission, presenting complaints, menopausal
status, parity, laterality, size of the tumor, stage of disease, serum tumor markers
(cancer antigen 125 [CA-125] and carcinoembryonic antigen), use of neoadjuvant chemotherapy
(NACT), date of surgery, presence of malignant ascites, peritoneal disease, whether
appendicectomy was done or not and the histopathological finding of the appendix,
lymph nodal dissection and the nodal status, pathological stage, grade of tumor, adjuvant
chemotherapy, recurrence, date of last follow-up, and status at follow-up. Data were
analyzed using simple statistical tools such as median values and SPSS version 22.0
(IBM Corp., Armonk, New York, USA). Kaplan–Meier plots were used to estimate the survival
distribution.
Results
A total of 958 malignant ovarian tumors were treated at our institute during this
period, out of which 758 were malignant epithelial ovarian cancers, 98 were germ cell
cancers, 30 were sex cord stromal tumors, and 48 were not classified.
Mucinous ovarian adenocarcinomas constituted 52 (5.43%) cases. Thirty-seven (71.2%)
patients presented with early-stage disease, out of which 27 (51.9%) were in stage
I and 10 (19.3%) were in stage II. Advanced-stage disease comprised 15 (28.8%) patients,
of whom 13 (25%) were in stage III and 2 (3.8%) were in stage IV ([Table 1]).
Table 1
The results of the various clinical characteristics studied
|
Characteristics
|
Values
|
|
Abbreviation: CA-125, cancer antigen 125.
|
|
Median age at presentation (years)
|
45 (15–73)
|
|
For early-stage disease (years)
|
42 (15–65)
|
|
For advanced-stage disease (years)
|
46 (36–73)
|
|
Medium serum CA-125 levels (IU/mL)
|
52.5
|
|
For early-stage disease (IU/mL)
|
47.1 (3.7–2,700)
|
|
For advanced-stage disease (IU/mL)
|
87.5 (20.7–8,490)
|
|
Median size of tumors (cm)
|
20 (6–30)
|
|
For early-stage disease (cm)
|
20 (6–30)
|
|
For advanced-stage disease (cm)
|
24 (9.9–33)
|
The most common presenting complaints were abdominal distension and pain. The distribution
was almost equal between premenopausal and postmenopausal women. Among the patients
with early-stage tumors, 86.5% underwent primary surgery, whereas 13.5% received NACT.
Stage IC and II tumors received adjuvant chemotherapy. Nearly 80% of the patients
with advanced-stage disease received NACT, whereas the remainder 20% underwent primary
cytoreduction. It was observed that among the 12 patients with advanced-stage disease
who received NACT, 6 (50%) progressed to chemotherapy and died without having cytoreductive
surgery. One patient had secondary cytoreduction. The chemotherapy regimens used were
paclitaxel and carboplatin doublet, single-agent carboplatin, cisplatin and cyclophosphamide
doublet, and liposomal doxorubicin and carboplatin doublet for six cycles.
The median duration of follow-up was 63 months (range: 1–138 months). The 5-year actuarial
overall survival (OS) for stages I, II, III, and IV disease was found to be 92.5,
70, 38.5, and 0%, respectively ([Table 2]).
Table 2
The survival outcomes in the early and advanced stages
|
Stage group
|
3-y OS (%)
|
5-y OS (%)
|
10-y OS (%)
|
|
Abbreviation: OS, overall survival.
|
|
Early (I and II)
|
89.2
|
86.2
|
69.0
|
|
Advanced (III and IV)
|
33.3
|
28.0
|
20.0
|
The age of the patient was found to be important in relation to the prognosis for
the disease. For the age group 60 years or more, the 5-year OS was 33.3% as opposed
to 75.9% for those aged <60 years (p = 0.004). When the patients aged under 30 years were considered, they were found
to have a 5-year and 10-year OS of 100 and 100% as compared with 64.1 and 48.3%, respectively,
for those aged 30 years or more (p = 0.01).
Two patients who underwent fertility-preserving surgery were alive without any evidence
of disease at 97 and 41 months of follow-up, respectively. One of them delivered a
healthy baby, whereas the other patient had polycystic ovarian disease and did not
conceive. No statistically significant difference was observed in the survival outcome
based on whether the serum CA-125 level was elevated or normal. The tumors that were
>13 cm and those that were unilateral fared much better than those <13 cm and bilateral
tumors or in cases where the laterality remained undetermined. Grade 1 and 2 tumors
had better survival than grade 3 tumors (p = 0.03) ([Table 3]).
Table 3
Survival outcome for various subgroups based on tumor characteristics
|
Subgroup
|
5-y OS (%)
|
|
Abbreviation: OS, overall survival.
|
|
<13 cm
|
74.8
|
|
>13 cm
|
33.3
|
|
Unilateral
|
80.5
|
|
Bilateral
|
60.0
|
|
Undetermined
|
0
|
|
Grade 1
|
75.0
|
|
Grade 2
|
84.0
|
|
Grade 3
|
41.7
|
Discussion
The population-based Madras Metropolitan Tumour Registry covers 4.65 million people.
The age-standardized ratio for carcinoma ovary per 100,000 population in Chennai is
8.2 as compared with 6.1 in the world.[4]
Mucinous adenocarcinomas of ovary are more often diagnosed at an early stage due to
which the OS is better compared with that of serous carcinomas.[5] In this study, 71.2% of tumors were in the early stages of disease, with a 5-year
OS of 86.2%. In contrast, when the disease presents at an advanced stage, the survival
is worse, probably owing to lesser sensitivity to platinum-based chemotherapy.[2]
[6] In our study, the patients with advanced-stage disease had a 5-year OS of 28%.
The mucinous histology is uncommon.[2] In our study, over a period of 8 years, only 52 cases were found comprising 5.43%
of the total cases. This makes randomized controlled trials of adequate statistical
power exploring therapeutic options, such as chemotherapy regimens, a daunting task.
There is no foolproof method to distinguish between primary mucinous adenocarcinomas
of the ovary and mucinous adenocarcinomas metastatic to the ovary, although many algorithms
using size and laterality as criteria and several immunohistochemical markers have
been used over time to aid in the distinction.[1]
[7]
[8]
[9] These are in addition to the several morphological characteristics, such as surface
involvement of ovary, a nodular growth pattern, presence of signet ring cells, hilar
involvement, an expansile or infiltrative growth pattern, presence of complex papillae,
and necrotic luminal debris, which have been described to make the differentiation.[10]
In our study, the mucinous adenocarcinomas have been deemed to have primarily arisen
from the ovary based on the clinical history and examination, imaging and endoscopy,
and histological features of the tumor.
mEOC responds poorly to platinum-based chemotherapy compared with its serous counterparts.[2] In our study, it was observed that 6 (50%) out of the 12 patients with advanced-stage
disease, who received NACT with the standard platinum-containing regimens, progressed
and died due to disease without getting cytoreductive surgery. This probably makes
us understand that the mucinous ovarian adenocarcinomas can be considered for upfront
complete cytoreductive surgery. However, such a comparison has not been made in our
retrospective study, in which one-fifth of the advanced-stage mEOC underwent primary
cytoreduction as opposed to the remaining 80% receiving NACT.
We understand that there are certain drawbacks to our study. Immunohistochemical studies
were not performed, even though it was understood that they could have helped in differentiating
between the primary and secondary tumors. This was because the use of these tests
has several limitations and does not completely eliminate misclassification. Besides,
Zaino et al reported that the median survival did not differ significantly between
the groups interpreted as primary or metastatic to the ovary for stage III and IV
disease.[11] We have also not compared the mucinous ovarian adenocarcinomas head-on with the
other histologies for the same study period.
Conclusion
Most of the mEOCs present in early stages and have good clinical outcomes. Patients
with advanced-stage disease do not respond well to standard chemotherapy regimens
in use and have poor survival figures. The use of complete primary cytoreduction should
be considered strongly in the place of interval cytoreduction for advanced mEOC
